December 4, 2019
The Ministry of Health, Labor and Welfare (MHLW) on December 3 ordered the revision of package inserts for four products including Chugai Pharmaceutical’s anti-PD-L1 antibody Tecentriq (atezolizumab) and AstraZeneca’s EGFR inhibitor Tagrisso (osimertinib). Hemophagocytic syndrome will be added to the...read more